{"entity":{"id":"azd0486","kind":"drug","name":"AZD0486","aka":[],"tldr":"AZD0486 is an experimental bispecific antibody from AstraZeneca in phase 3 trials for diffuse large B-cell lymphoma, aimed at CD19 and CD3.","summary":"AZD0486 (TNB-486) is a bispecific antibody developed by AstraZeneca. Its targets are CD19 and CD3 (the sponsor names CD19 x CD3). It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT07215585 (AZD0486 1L Therapy for Elderly or Unfit Participants With LBCL), in diffuse large B-cell lymphoma. The largest, NCT07215585, plans to enrol 420 participants with primary completion expected 2030-06-10. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-3","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of AZD0486","url":"https://clinicaltrials.gov/search?intr=TNB-486"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["dlbcl"],"sections":[],"technologies":[],"targets":["cd19","cd3"],"drugs":[],"companies":["astrazeneca"],"institutions":[],"pathways":[],"terms":[],"trials":["nct07215585","nct06549595","nct07509151","nct06526793","nct06564038"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"code":"TNB-486","modality":"bispecific antibody","mechanism":"Bispecific antibody directed at CD19 and CD3, as stated in the ClinicalTrials.gov intervention record; the detailed mechanism is not stated.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/azd0486/","neighbours":{"cancer":[{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"}],"target":[{"id":"cd19","kind":"target","name":"CD19","route":"/targets/cd19/"},{"id":"cd3","kind":"target","name":"CD3","route":"/targets/cd3/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"}],"trial":[{"id":"nct06564038","kind":"trial","name":"A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies","route":"/trials/nct06564038/"},{"id":"nct06549595","kind":"trial","name":"A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients","route":"/trials/nct06549595/"},{"id":"nct07215585","kind":"trial","name":"AZD0486 1L Therapy for Elderly or Unfit Participants With LBCL","route":"/trials/nct07215585/"},{"id":"nct06526793","kind":"trial","name":"Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL","route":"/trials/nct06526793/"},{"id":"nct07509151","kind":"trial","name":"Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin He","route":"/trials/nct07509151/"}]}}